Industry News
Pharmaceutical Industry News
Boosted again by strong sales of…
Boosted again by strong sales of Skyrizi and Rinvoq, AbbVie has jacked up its revenue forecast for 2025 for the third straight quarter. The Illinois drugmaker has raised its guidance by $400 million, now expecting
The American Academy of Pediatrics…
The American Academy of Pediatrics on Friday said it does not recommend the routine use of leucovorin for children with autism, citing limited evidence.
Gilead’s long-acting…
Gilead’s long-acting pre-exposure prophylaxis med Yeztugo has garnered $54 million in sales since its June launch in the U.S., the company reported, bolstering its HIV franchise as cell therapy sales continue to decline.
The regulatory framework around…
The regulatory framework around biopharmaceutical manufacturing is exacting and continuously evolving. Companies must meet diverse global requirements while staying agile enough to deliver on accelerated clinical and commercial timelines
Takeda tightened its pipeline in…
Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 study. Roche licensed a respiratory bispecific candidate in a potential $1 billion-plus deal. And
As Biogen continues to carve out…
As Biogen continues to carve out new markets for its recent launches, the company's legacy multiple sclerosis franchise is holding steady in the face of generic pressure.
With vaccine sales on the decline…
With vaccine sales on the decline across the industry, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. But in the third quarter, the company recorded encouraging sales of the vaccine,
Bristol Myers Squibb’s highly…
Bristol Myers Squibb’s highly anticipated Cobenfy just finished its first trip around the sun as an approved drug, posting results in line with expectations that leave investors wondering when an inflection point might arrive.
Despite the largest U.S. pharmacy…
Despite the largest U.S. pharmacy benefit manager knocking Zepbound off its formulary this summer, sales of Lilly’s dual-action obesity med continue to impress, thanks in no small part to the company’s direct-to-consumer sales channel LillyDirect.
CSL Seqirus, the vaccine unit of…
CSL Seqirus, the vaccine unit of Australian biotech CSL, signed a pact to provide Saudi Arabia with cell-based influenza shots and to help establish its production in-country. The move comes as part of an effort
F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.
Riding its March expansion into…
Riding its March expansion into the heart condition of ATTR-CM, sales of Amvuttra again came above analysts’ consensus estimates in the third quarter.
The FDA has revealed a set of…
The FDA has revealed a set of measures designed to increase the availability of biosimilars in the United States and in turn reduce the price of biologic medicines after they lose patent protection. In new
Havas Media Network’s Holly Dunn…
Havas Media Network’s Holly Dunn on how pharma can build trust, equity, and smarter patient connections in today’s evolving health marketplaces.
After a progression-free survival…
After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.
Akebia Therapeutics has scrapped…
Akebia Therapeutics has scrapped plans for a trial that could have expanded the patient population for its new anemia drug Vafseo, the company said.
Emma Walmsley and her GSK CEO…
Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter.
In a bid to ensure that the widest…
In a bid to ensure that the widest swath of people with generalized myasthenia gravis (gMG) can benefit from its blockbuster medicine, argenx is heading to the FDA with positive data in a subset of
Eli Lilly has revealed a plan to…
Eli Lilly has revealed a plan to spend $1.2 billion to upgrade its plant in Carolina, Puerto Rico. The investment will add 100 manufacturing jobs and bolster the company’s capacity to produce oral drugs, including
Texas demanda a los fabricantes de Tylenol por supuesto encubrimiento de riesgos de autismo
La demanda sostiene que las empresas ocultaron deliberadamente a los consumidores pruebas sobre la relación del paracetamol con el autismo y el TDAH, lo cual no está demostrado.